Skip to content
Axmed

Impact

4.2 million patients reached in 2025

How we count that, what it saved the health systems buying through us, and where we fell short. Reported every year in the impact report and the stakeholder letter.

In numbers

The year, line by line

Where a comparison with the year before genuinely exists, the two sit side by side. Where it does not, the figure stands alone rather than against an invented baseline.

4.2M

patients served

+453% vs 2024

The first year the marketplace ran at scale: more patients served in twelve months than in everything before it, and the first full impact report to account for how.

Where we have a comparison

  • 2024
  • 2025

Patients served

+453%vs 2024

2024≈760,000
20254.2M

The 2024 figure is calculated back from the published increase of 453%, so it is approximate.

Topline revenue growth

12×vs annualised 2024

20241× baseline
202512×

Measured against annualised 2024. Including performance obligations the figure is 22×.

Each metric is scaled against its own two years, not against the other metrics.

The full year

Patients served
+453% vs 2024
4.2M
Topline revenue growth
vs annualised 2024; 22× including performance obligations
12×
Average cost savings
22% median
35%
Deals completed
54
Medicines shipped
1,800+ t
Marketplace offerings
medicines and health products
5,000+

The report

Impact Report 2025

The method behind every number, country by country, and an account of what did not work.

≈760,000

patients served

approximate

The year the marketplace was built rather than measured: incorporation in Kenya, the first one-ton shipment, and the beta the 2025 numbers are counted from.

Axmed began publishing a full impact report with 2025, so 2024 is here as the baseline that year is measured against. Only the figures that were genuinely published appear below. The rest were not counted at the time, and are not estimated here to fill the table.

The full year

Patients served
calculated back from the published 2025 increase of 453%, so it is approximate
≈760,000

Axmed published its first full impact report for 2025. There is no report for this year.

Voices

What the people we work with say

Procurers, distributors and research institutes who have run real volume through the platform.

Through our partnership with Axmed, we have a greater impact on improving maternal and child health outcomes and ending preventable deaths in some of Africa's most under-resourced communities.
Santiago Sedaca
CEO, LifeNet International
Axmed has proven that a strong model, backed by operational excellence and deep commitment, can deliver real impact even within complex environments. They have consistently demonstrated an exceptional ability to navigate the complexities of the global healthcare supply chain, developing pragmatic strategies that produce measurable and sustainable impact.
Denise Tuiime Mutambi
Director Planning and Procurement, JMS
At GMRI, we engaged Axmed Global Health Advisory to work with us on the go-to-market / access strategy. Their professionalism, experience, working relationships with our teams and knowledge have been outstanding.
Dr. Patrice Matchaba
Former CEO and board member, Gates Medical Research Institute

Read the full impact report

The method behind every number, country by country, and what we got wrong.